Cullinan Therapeutics, Inc. Cash Flow Statement
CGEM / Health Care|5 years of annual SEC 10-K data (FY2020-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
Cullinan Therapeutics, Inc. used $145M in operating cash flow and negative free cash flow of $145M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.33 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Net Income | -$167.4M | -$153.2M | $111.2M | -$51.8M | -$51.8M |
| Depreciation & Amortization | $306.0K | $310.0K | $93.0K | $62.0K | $62.0K |
| Operating Cash Flow | -$145.3M | -$134.3M | -$126.7M | -$29.8M | -$29.8M |
| Capital Expenditures | $0 | $208.0K | $1.1M | $10.0K | $10.0K |
| Free Cash Flow | -$145.3M | -$134.5M | -$127.8M | -$29.8M | -$29.8M |
| Share Buybacks | - | - | - | $6.6M | $6.6M |